Cargando…
Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries. It has recently been shown that the homogeneity of the chromatin landscape between CLL cells contrasts with the important observed genetic heterogeneity of the disease. To gain further insight into the consequence...
Autores principales: | Holmes, Katie B., Sadreev, Ildar I., Rawstron, Andy C., Munir, Tal, Westhead, David R., Hillmen, Peter, Lefevre, Pascal F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510766/ https://www.ncbi.nlm.nih.gov/pubmed/31076570 http://dx.doi.org/10.1038/s41389-019-0142-2 |
Ejemplares similares
-
DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia
por: Thomas, Fraser, et al.
Publicado: (2020) -
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019) -
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
por: Jones, Jeffrey A., et al.
Publicado: (2017) -
Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
por: Hillmen, Peter, et al.
Publicado: (2021) -
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
por: Jones, Jeffrey, et al.
Publicado: (2018)